Cargando…

Immunotherapy-Based Therapeutic Strategies for Recurrent Advanced Squamous Cell Carcinoma of the Head and Neck: A Case Report and Literature Review

We present a patient with locoregionally advanced laryngeal carcinoma, who experienced recurrence 2 months after surgery. We exploratively treated this patient with immunotherapy combined with targeted therapy with or without radiation therapy. The patient exhibited a significant and durable respons...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nie, Hao, Chen, Ting, He, Kefei, Liang, Chanjin, Guo, Wei, Shi, Xingyuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335395/ https://www.ncbi.nlm.nih.gov/pubmed/34367140 http://dx.doi.org/10.3389/fimmu.2021.680327

Ejemplares similares

Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus
por: Wang, Huanhuan, et al.
Publicado: (2021)

Case report: Patient specific combination of surgery and immunotherapy in advanced squamous cell carcinoma of the head and neck – a case series and review of literature
por: Olmos, Manuel, et al.
Publicado: (2022)

Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Hsieh, Ronan W., et al.
Publicado: (2021)

An Immunogenic Cell Death-Related Classification Predicts Prognosis and Response to Immunotherapy in Head and Neck Squamous Cell Carcinoma
por: Wang, Xinwen, et al.
Publicado: (2021)

Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma
por: Cristina, Valerie, et al.
Publicado: (2019)

EGFR Mutation and 11q13 Amplification Are Potential Predictive Biomarkers for Immunotherapy in Head and Neck Squamous Cell Carcinoma
por: Dou, Shengjin, et al.
Publicado: (2022)

A novel neutrophil extracellular trap signature to predict prognosis and immunotherapy response in head and neck squamous cell carcinoma
por: Li, Qilin, et al.
Publicado: (2022)

CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma
por: Ciulean, Ioana Sonya, et al.
Publicado: (2023)

Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Borel, Christian, et al.
Publicado: (2020)

Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma
por: Qi, Xinmeng, et al.
Publicado: (2017)

The Tumor Immune Microenvironment Architecture Correlates with Risk of Recurrence in Head and Neck Squamous Cell Carcinoma
por: Weed, Donald T., et al.
Publicado: (2023)

Immunotherapy for head and neck squamous cell carcinoma
por: Fuereder, Thorsten
Publicado: (2016)

Immunotherapy for Head and Neck Squamous Cell Carcinoma
por: Moskovitz, Jessica, et al.
Publicado: (2018)

Immunotherapy in Head and Neck Squamous Cell Cancer
por: Denaro, Nerina, et al.
Publicado: (2018)

Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies
por: Cavalieri, Stefano, et al.
Publicado: (2021)

Recent Advances in Immunotherapy for Patients with Head and Neck Cutaneous Squamous Cell Carcinoma
por: Khorasanchi, Adam, et al.
Publicado: (2022)

Integrated multi-omics analysis identifies CD73 as a prognostic biomarker and immunotherapy response predictor in head and neck squamous cell carcinoma
por: Shen, Ao, et al.
Publicado: (2022)

The prognostic impact of the immune signature in head and neck squamous cell carcinoma
por: Baysal, Hasan, et al.
Publicado: (2022)

On the Road to Immunotherapy—Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor Antibodies
por: Ward, Frank J., et al.
Publicado: (2018)

Efficacy and safety of pembrolizumab with preoperative neoadjuvant chemotherapy in patients with resectable locally advanced head and neck squamous cell carcinomas
por: Wang, Kai, et al.
Publicado: (2023)

Developing an immunotherapy strategy for the effective treatment of patients with squamous cell carcinoma of the head and neck
por: Moudgil, Tarsem, et al.
Publicado: (2013)

Evolving treatment paradigms in recurrent and metastatic head and neck squamous cell carcinoma: the emergence of immunotherapy
por: Faraji, Farhoud, et al.
Publicado: (2023)

Induction chemotherapy combined with immunotherapy in locally advanced head and neck squamous cell carcinoma
por: Li, Xia, et al.
Publicado: (2021)

The Common Costimulatory and Coinhibitory Signaling Molecules in Head and Neck Squamous Cell Carcinoma
por: Liao, Peng, et al.
Publicado: (2019)

TNF Patterns and Tumor Microenvironment Characterization in Head and Neck Squamous Cell Carcinoma
por: Long, Qian, et al.
Publicado: (2021)

The role of nanotherapy in head and neck squamous cell carcinoma by targeting tumor microenvironment
por: Zhang, Ye, et al.
Publicado: (2023)

The Optimal Second-Line Systemic Treatment Model for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: A Bayesian Network Meta-Analysis
por: Zhan, Ze-Jiang, et al.
Publicado: (2021)

Pseudoprogression in the era of immunotherapy-based strategies for recurrent head and neck squamous cell carcinoma achieving complete response: A case report
por: Zhou, Jiawei, et al.
Publicado: (2023)

The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches
por: Economopoulou, Panagiota, et al.
Publicado: (2017)

CD244 represents a new therapeutic target in head and neck squamous cell carcinoma
por: Agresta, Laura, et al.
Publicado: (2020)

The strategies of NLRP3 inflammasome to combat Toxoplasma gondii
por: Yoon, Chanjin, et al.
Publicado: (2022)

Real-World Experience of Immunotherapy from India in Recurrent Squamous Cell Carcinoma of Head and Neck Cancer
por: Abbas, Waseem, et al.
Publicado: (2021)

New Challenges in Evaluating Outcomes after Immunotherapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
por: Alberti, Andrea, et al.
Publicado: (2022)

Therapeutic strategies of different HPV status in Head and Neck Squamous Cell Carcinoma
por: Sun, Yingming, et al.
Publicado: (2021)

Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck
por: Pivot, X, et al.
Publicado: (2001)

DCBLD1 Overexpression Is Associated With a Poor Prognosis in Head and Neck Squamous Cell Carcinoma
por: Fu, Ling-ling, et al.
Publicado: (2022)

Prognostic value of the immunohistochemical score based on four markers in head and neck squamous cell carcinoma
por: Xu, Qing-Qing, et al.
Publicado: (2023)

Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer
por: Hughes, Ryan T, et al.
Publicado: (2023)

Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma
por: Flanagan, Kevin C., et al.
Publicado: (2023)

Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy
por: Sadeghirad, Habib, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mk6n7jdae7b0c3lmsa8jrosnbc